For some time, semaglutide was a top performer in the GLP-1 space, showing impressive weight loss in its major clinical trials
There was a lot of pent-up demand, and I think health plans started to see it in 2023
In the intracellular milieu, the meningococcus has been found to interact with Dynein Light Chain Tctex-Type 1 (DYNLT1) component of the motor protein dynein through a middle region of HrpA (Tal et al., 2022)
for example, Roche has strengthened its pipeline through the acquisition of Carmot Therapeutics and a partnership with Zealand Pharma
PMID: 22949491, DOI: 10.1161/circoutcomes.111.964569
That's why it's important to review your prescription coverage, understand your options, and make sure your plan fits your needs